Gilead Sciences Acquires Polθ ATPase Inhibitor RP-3467 for $30 Million
Gilead Sciences, Inc. has reached a landmark agreement to acquire the polymerase theta (Polθ) ATPase inhibitor RP-3467 from Repare Therapeutics Inc. The total value of the transaction is set at $30 million, marking a significant milestone in the oncology sector.
Details of the Acquisition
Under the agreement, Repare will receive an upfront payment of $25 million. Additionally, there is a provision for a further $5 million payment contingent upon the completion of specified technology transfer activities. This acquisition enhances Gilead’s portfolio, combining its oncology research capabilities with the innovative features of RP-3467.
Strategic Importance
Steve Forte, the President and CEO of Repare Therapeutics, emphasized the significance of this deal, noting it as the third major portfolio transaction for the company within the year. The acquisition not only boosts Gilead’s oncology pipeline but also provides Repare with increased liquidity to advance its ongoing clinical trials.
About RP-3467
RP-3467 is a small molecule inhibitor that targets Polθ. It aims to exploit synthetic lethality, particularly in cancers linked to BRCA mutations and other genomic alterations. Currently, the drug is undergoing evaluation in the POLAR Phase 1 clinical trial. This trial assesses the compound’s safety and efficacy in treating various cancers, including:
- Locally advanced or metastatic epithelial ovarian cancer
- Metastatic breast cancer
- Metastatic castration-resistant prostate cancer
- Pancreatic adenocarcinoma
Impact on Repare Therapeutics Investors
This acquisition is expected to positively influence Repare’s financial structure. With the upfront payment enhancing its cash reserves, Repare anticipates an estimated cash payout of approximately $2.20 per common share for its shareholders upon the closing of a separate transaction with XenoTherapeutics, Inc.
Future Prospects
The agreement with Gilead underscores the continued evolution of cancer therapies and highlights the potential of RP-3467 in oncology. As Gilead leverages its expertise to advance this drug within its clinical framework, the partnership promises to foster significant advancements in cancer treatment options.
